Phase 3 data show intismeran plus pembrolizumab reduced recurrence or death risk by 42% in patients with resected stage IIB-IV melanoma.
|Articles|May 3, 2023
SLIDESHOW: Recognizing National Skin Cancer and Melanoma Awareness Month
Author(s)Lauren Buchanan, MA, Managing Editor
May is National Skin Cancer and Melanoma Awareness Month. We have skin cancer at the forefront of our coverage this month. Here is a recap of the latest news about skin cancer research, studies, and more.
Advertisement
Advertisement
Related to this article
Shannon Trotter, DO, moderated a Dermatology Times Case-Based Roundtable event on how pharmacokinetics, adverse event timing, and trial response criteria should shape hedgehog pathway inhibitor selection in advanced BCC.
Two-year oral IL-23 data, GLP-1 biomarker findings, and a nonsurgical option for superficial basal cell carcinoma headline the sessions covered in Las Vegas.
Prospective data suggest DecisionDx-Melanoma may help refine SLNB decisions and identify recurrence risk beyond conventional staging.
Dermatology PAs unpack 4 frightening skin care myths and trends, from sunscreen misinformation and citrus DIYs to overusing actives and beef tallow.
The approval expands the IL-23 inhibitor’s indications beyond moderate-to-severe plaque psoriasis to include adults with active psoriatic arthritis.
Find out what skin care products and aesthetic innovations clinicians are recommending to patients for the month of October.
Clinician FAQ on remibrutinib's FDA approval in symptomatic dermographism: RemIND efficacy, mechanism, safety, and supporting CSU evidence.
Advertisement
Advertisement
Trending on Dermatology Times
1
FDA Approves Tildrakizumab for Active Psoriatic Arthritis
2
Beyond Dry Skin: Rethinking Common Eczema Misconceptions
3
FAQ: Remibrutinib (Rhapsido) Becomes First FDA-Approved Treatment for a Chronic Inducible Urticaria
4
How Approvals, Setbacks, and a Crowded Pipeline Are Reshaping the AD Treatment Landscape
5